Marina Onda
Overview
Explore the profile of Marina Onda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
0
Followers
0
Related Specialty
Related Specialty
Co-Authors
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Onda M, Hagino T, Saeki H, Fujimoto E, Kanda N
J Dermatol
. 2025 Mar;
PMID: 40087893
Bimekizumab, an interleukin (IL)-17A/IL-17F inhibitor, is effective for moderate-to-severe psoriasis. However, long-term maintenance of early treatment outcomes is not examined in real-world settings, with no analyses stratified by dosing intervals...
2.
Hagino T, Uchiyama A, Onda M, Kosaka K, Araki T, Motegi S, et al.
Dermatitis
. 2025 Feb;
PMID: 39977111
Real-world data on the effectiveness and safety of lebrikizumab for atopic dermatitis (AD) are limited. To evaluate the real-world effectiveness and safety of lebrikizumab on Japanese patients with AD. This...
3.
Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N
J Dermatol
. 2025 Jan;
PMID: 39873274
Deucravacitinib, an oral tyrosine kinase 2 inhibitor, is effective for psoriasis. However, long-term real-world effectiveness stratified by age and body mass index (BMI) has not been precisely examined. This study...
4.
Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N
J Dermatol
. 2024 Dec;
52(3):551-555.
PMID: 39723549
The tyrosine kinase 2 inhibitor deucravacitinib is therapeutically effective for psoriasis. However, predictive factors for high responses to deucravacitinib have not been examined in a real-world clinical study. Our study...
5.
Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N
Eur J Dermatol
. 2024 Nov;
34(5):525-532.
PMID: 39589036
Tralokinumab is a human monoclonal anti-interleukin-13 antibody approved as systemic treatment for atopic dermatitis (AD). We aimed to evaluate effectiveness and safety of tralokinumab for AD in real-world clinical practice....
6.
Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N
Dermatitis
. 2024 Oct;
PMID: 39361494
Tralokinumab, a monoclonal anti-IL-13 antibody, is approved for treating atopic dermatitis (AD). Real-world data on its effectiveness and safety are limited. To evaluate the real-world effectiveness and safety of tralokinumab...
7.
Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N
J Dermatol
. 2024 Aug;
51(12):1658-1664.
PMID: 39133570
Psoriasis is a complex, chronic inflammatory skin disease that significantly impacts patients' quality of life (QOL), especially in cases of genital, nail, and scalp psoriasis. Bimekizumab is an inhibitor of...
8.
Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N
Clin Exp Dermatol
. 2024 Aug;
50(1):130-133.
PMID: 39096269
Psoriasis is a chronic, complicated inflammatory skin disease. Genital, nail and scalp lesions with psoriasis are difficult to treat and can considerably impair patients' quality of life (QoL). Deucravacitinib, an...